T1期胃神经内分泌癌转移风险及内镜与手术治疗的生存比较
基于SEER数据库205例T1期胃神经内分泌癌患者,研究发现肿瘤>20 mm是转移的最显著危险因素(OR 18.64)。对于黏膜受累且直径≤2 cm的T1N0M0患者,内镜治疗与手术的10年总生存率和癌症特异性生存率无显著差异,提示内镜治疗可能足够。
要点
- 肿瘤>20 mm是T1期胃神经内分泌癌转移的最显著危险因素。
- 黏膜受累且肿瘤≤20 mm者未见转移,内镜治疗可能足够。
- T1N0M0患者内镜治疗与手术的10年生存率无显著差异。
核心结论
- 肿瘤>20 mm是T1期胃神经内分泌癌转移的最显著危险因素。
- 对于黏膜受累且肿瘤≤2 cm的T1N0M0患者,内镜治疗可能足够。
研究设计与样本
- 回顾性队列研究,从SEER数据库收集205例T1期胃神经内分泌癌患者。
- 采用Logistic回归分析转移的独立预测因素,并计算癌症特异性生存和总生存。
主要发现
- 黏膜受累且肿瘤≤20 mm者无转移(0%,0/49)。
- 肿瘤>20 mm的转移风险OR为18.64(95%CI 4.01-86.68,P<0.001)。
- T1N0M0患者中,黏膜受累组内镜治疗与手术的10年OS分别为91.56%和87.50%(P=0.62),黏膜下受累组分别为57.33%和77.83%(P=0.11)。
- 10年CSS:黏膜受累组内镜治疗97.30% vs 手术100%(P=0.51),黏膜下组97.62% vs 86.49%(P=0.65)。
关键数值与推荐
- 肿瘤>20 mm是转移的最显著危险因素(OR 18.64;95%CI 4.01-86.68;P<0.001)。
- 黏膜受累且肿瘤≤20 mm者未见转移(0%,0/49)。
临床怎么用
- 对于T1期胃神经内分泌癌,应评估肿瘤大小,>20 mm者转移风险高。
- 黏膜受累且肿瘤≤2 cm的T1N0M0患者可考虑内镜治疗。
- 内镜治疗与手术的长期生存相似,但需个体化决策。
局限性
- 研究为回顾性设计,存在选择偏倚可能。
- 样本来自SEER数据库,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gastrectomy with lymphadenectomy is recommended for early gastric Neuroendocrine carcinoma (G-NEC). We attempted to determine the prevalence and risk factors of metastasis of T1 G-NEC and compare the long-term survival of patients after receiving endoscopic therapy (ET) and radical surgery. METHODS: In this study, 205 patients in total with T1 G-NEC were collected from the Surveillance Epidemiology and End Result database. Independent predictors of metastasis were identified by Logistic regression analysis, followed by the calculation of both cancer-specific survival (CSS) and overall survival (OS). RESULTS: Twenty-five patients (12.2%) were burdened with metastasis at initial diagnosis, with a prevalence of 5.2% (3/58) in mucosa lesions and 16.2% (16/99) in submucosa lesions (P = 0.045). No metastasis was detected in lesions with mucosa involvement and tumors ≦ 20 mm (0%, 0/49). The most significant risk factor for metastasis was tumors > 20 mm [odds ratio (OR) 18.64; 95% confidence interval (CI) 4.01-86.68; P < 0.001]. For patients with T1N0M0 G-NEC who received ET or surgery, the 10-year OS was similar between the mucosa extension and submucosa extension groups, which was 91.56% in ET group vs 87.50% in surgery group (P = 0.62) and 57.33% vs 77.83% (P = 0.11), respectively. In addition, the 10-year CSS was also similar between the mucosa extension and submucosa extension groups with 97.30% in ET vs 100% in surgery (P = 0.51) and 97.62% vs 86.49% (P = 0.65). CONCLUSIONS: In G-NEC, tumors > 20 mm were considered as the most significant risk factor for metastasis. ET seemed adequate for the lesions with mucosa involvement and size ≦ 2 cm.
引用
- Ye H, Yuan Y, Chen P, et al. Risk factors for metastasis and survival of patients with T1 gastric neuroendocrine carcinoma treated with endoscopic therapy versus surgical resection. Surg Endosc. 2022. PMID: 35507062. doi:10.1007/s00464-022-09190-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。